These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 17532288)

  • 21. Cost-Effectiveness Analysis of Microscopic and Endoscopic Transsphenoidal Surgery Versus Medical Therapy in the Management of Microprolactinoma in the United States.
    Jethwa PR; Patel TD; Hajart AF; Eloy JA; Couldwell WT; Liu JK
    World Neurosurg; 2016 Mar; 87():65-76. PubMed ID: 26548828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term outcome of macroprolactinomas.
    Képénékian L; Cebula H; Castinetti F; Graillon T; Brue T; Goichot B
    Ann Endocrinol (Paris); 2016 Dec; 77(6):641-648. PubMed ID: 27641080
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyperprolactinemia and prolactinoma.
    Romijn JA
    Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Current diagnosis and treatment of hyperprolactinemia].
    Melgar V; Espinosa E; Sosa E; Rangel MJ; Cuenca D; Ramírez C; Mercado M
    Rev Med Inst Mex Seguro Soc; 2016; 54(1):111-21. PubMed ID: 26820213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
    Di Sarno A; Landi ML; Cappabianca P; Di Salle F; Rossi FW; Pivonello R; Di Somma C; Faggiano A; Lombardi G; Colao A
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Bromocriptine monotherapy of a prolactinoma causing erectile dysfunction].
    López Cubillana P; Hita Rosino E; Asensio Egea L; Rigabert Montiel M; Hita Villaplana G; Server Pastor G; Server Falgás G
    Arch Esp Urol; 1997 Jun; 50(5):526-8. PubMed ID: 9382597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ropinirole for the Treatment of Hyperprolactinemia: A Dose-Escalation Study of Efficacy and Tolerability.
    Heneghan LJ; Tsang A; Dimino C; Khandji AG; Panigrahi SK; Page-Wilson G
    J Clin Endocrinol Metab; 2024 Jan; 109(2):e667-e674. PubMed ID: 37715962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of prolactinomas during pregnancy.
    Molitch ME
    J Reprod Med; 1999 Dec; 44(12 Suppl):1121-6. PubMed ID: 10649822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
    Primeau V; Raftopoulos C; Maiter D
    Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study.
    Höfle G; Gasser R; Mohsenipour I; Finkenstedt G
    Exp Clin Endocrinol Diabetes; 1998; 106(3):211-6. PubMed ID: 9710362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.
    Hu J; Zheng X; Zhang W; Yang H
    Pituitary; 2015 Oct; 18(5):745-51. PubMed ID: 25500765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surgery, dopamine agonist therapy of combined treatment--results in prolactinoma patients after a 12 month follow-up.
    Hildebrandt G; Bauer T; Stracke H; Fassbender WJ; Mueller HW; Agnoli AL; Federlin K; Roosen K
    Zentralbl Neurochir; 1992; 53(3):123-34. PubMed ID: 1414079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyperprolactinemia.
    Biller BM
    Int J Fertil Womens Med; 1999; 44(2):74-7. PubMed ID: 10338264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discrimination of prolactinoma from hyperprolactinemic non-functioning adenoma.
    Hong JW; Lee MK; Kim SH; Lee EJ
    Endocrine; 2010 Feb; 37(1):140-7. PubMed ID: 20963563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal.
    Santharam S; Fountas A; Tampourlou M; Arlt W; Ayuk J; Gittoes N; Toogood A; Karavitaki N
    Clin Endocrinol (Oxf); 2018 Sep; 89(3):346-353. PubMed ID: 29894000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral and injectable long-lasting bromocriptine preparations in hyperprolactinemia: comparison of their prolactin lowering activity, tolerability and safety.
    Merola B; Colao A; Caruso E; Sarnacchiaro F; Briganti F; Lancranjan I; Lombardi G; Schettini G
    Gynecol Endocrinol; 1991 Dec; 5(4):267-76. PubMed ID: 1796748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term Discontinuation of Dopamine Agonist Treatment in Patients with Prolactinomas Revisited.
    Sosa-Eroza E; Espinosa-Cárdenas E
    Arch Med Res; 2023 Dec; 54(8):102893. PubMed ID: 37806785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Usefulness of cabergoline in patients with prolactinemia and resistant or intolerant to bromocriptine].
    Velázquez-Chávez FJ; Tapia-González Mde L; González-Bárcena D
    Cir Cir; 2009; 77(3):173-7. PubMed ID: 19671268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis.
    Xia MY; Lou XH; Lin SJ; Wu ZB
    Endocrine; 2018 Jan; 59(1):50-61. PubMed ID: 29043560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medical treatment of prolactinomas.
    Molitch ME
    Endocrinol Metab Clin North Am; 1999 Mar; 28(1):143-69, vii. PubMed ID: 10207689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.